Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 61 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Chimerix Inc | CMRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.95 | 06:08:53 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.95 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 2 | 61 | - | 0.88 - 1.57 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:36:25 | 60 | US$ 0.94 | USD |
Chimerix Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 84.75M | 89.21M | - | 324k | -82.1M | -0.92 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Chimerix News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.90 | 0.9698 | 0.8815 | 0.9252166 | 242,214 | 0.05 | 5.56% |
| 1 Month | 1.05 | 1.07 | 0.88 | 0.9443338 | 279,586 | -0.10 | -9.52% |
| 3 Months | 0.912 | 1.30 | 0.88 | 1.06 | 440,989 | 0.038 | 4.17% |
| 6 Months | 0.9395 | 1.30 | 0.88 | 1.01 | 397,964 | 0.0105 | 1.12% |
| 1 Year | 1.21 | 1.57 | 0.88 | 1.14 | 640,780 | -0.26 | -21.49% |
| 3 Years | 8.82 | 9.2899 | 0.88 | 2.87 | 1,348,714 | -7.87 | -89.23% |
| 5 Years | 2.71 | 11.5696 | 0.88 | 3.22 | 1,069,593 | -1.76 | -64.94% |
Chimerix Description
| Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. |
